MENDUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4745 SEK | +0.96% |
|
-5.10% | -9.27% |
| 16/04 | Mendus AB Announces Board Changes | CI |
| 27/03 | Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML | CI |
| Sales 2024 * | - | Sales 2025 * | 264M 24.13M 2.01B | Capitalization | 478M 43.69M 3.64B |
|---|---|---|---|---|---|
| Net income 2024 * | -130M -11.88M -991M | Net income 2025 * | 132M 12.07M 1.01B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 59.34M 5.42M 452M | Net cash position 2025 * | 192M 17.53M 1.46B | EV / Sales 2025 * | 1.08 x |
| P/E ratio 2024 * |
-3.95
x | P/E ratio 2025 * |
3.8
x | Employees | 30 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mendus AB
More press releases
| 1 day | +0.96% | ||
| 1 week | -5.10% | ||
| Current month | +5.44% | ||
| 1 month | +3.15% | ||
| 3 months | -2.27% | ||
| 6 months | +34.23% | ||
| Current year | -9.27% |
1 week
0.46
0.50
1 month
0.440.56
Current year
0.390.56
1 year
0.301.85
3 years
0.306.34
5 years
0.3016.44
10 years
0.3046.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 74 | 01/02/01 | |
Erik Manting
CEO | Chief Executive Officer | 53 | - |
Lotta Ferm
DFI | Director of Finance/CFO | 58 | 28/21/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 01/13/01 | |
Helén Tuvesson
BRD | Director/Board Member | 62 | 01/20/01 |
Hans Preusting
BRD | Director/Board Member | 62 | 01/21/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.4745 | +0.96% | 1,277,052 |
| 25/24/25 | 0.47 | -4.08% | 1,613,893 |
| 24/24/24 | 0.49 | -1.31% | 908,965 |
| 23/24/23 | 0.4965 | +1.33% | 607,145 |
| 22/24/22 | 0.49 | -2.00% | 1,110,513 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:53 pm IST
More quotes
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patientâs own immune system against cancer. The Companyâs programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Calendar
17/05/2024
- Annual General Meeting
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.27% | 43.59M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- IMMU Stock
